- Home
- MYNZ vs BGLC Comparison
MYNZ vs BGLC Comparison
Compare MYNZ & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- BGLC
- Stock Information
- Founded
- MYNZ 2021
- BGLC 2017
- Country
- MYNZ Germany
- BGLC Malaysia
- Employees
- MYNZ N/A
- BGLC N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- BGLC Medical Specialities
- Sector
- MYNZ Health Care
- BGLC Health Care
- Exchange
- MYNZ Nasdaq
- BGLC Nasdaq
- Market Cap
- MYNZ N/A
- BGLC 7.6M
- IPO Year
- MYNZ 2021
- BGLC N/A
- Fundamental
- Price
- MYNZ $0.31
- BGLC $0.38
- Analyst Decision
- MYNZ Buy
- BGLC
- Analyst Count
- MYNZ 2
- BGLC 0
- Target Price
- MYNZ $3.00
- BGLC N/A
- AVG Volume (30 Days)
- MYNZ 2.3M
- BGLC 116.1K
- Earning Date
- MYNZ 11-14-2024
- BGLC 11-20-2024
- Dividend Yield
- MYNZ N/A
- BGLC N/A
- EPS Growth
- MYNZ N/A
- BGLC N/A
- EPS
- MYNZ N/A
- BGLC N/A
- Revenue
- MYNZ $917,203.00
- BGLC $9,183,168.00
- Revenue This Year
- MYNZ $36.69
- BGLC N/A
- Revenue Next Year
- MYNZ $91.67
- BGLC N/A
- P/E Ratio
- MYNZ N/A
- BGLC N/A
- Revenue Growth
- MYNZ 16.23
- BGLC N/A
- 52 Week Low
- MYNZ $0.19
- BGLC $0.31
- 52 Week High
- MYNZ $3.39
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- MYNZ 51.63
- BGLC 41.00
- Support Level
- MYNZ $0.28
- BGLC $0.38
- Resistance Level
- MYNZ $0.33
- BGLC $0.49
- Average True Range (ATR)
- MYNZ 0.05
- BGLC 0.02
- MACD
- MYNZ 0.00
- BGLC -0.00
- Stochastic Oscillator
- MYNZ 42.69
- BGLC 32.66
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.